Patents Assigned to AstraZeneca
  • Therapeutic Compounds 570
    Publication number: 20090099195
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, and R5 and are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: May 5, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Malken Bayrakdarian, Christophe Buon, Louis-David Cantin, Yun-Jin Hu, Xuehong Luo, Vijayaratnam Santhakumar, Miroslaw Tomaszewski
  • ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF
    Publication number: 20090099210
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor
    Publication number: 20090099187
    Abstract: The present invention relates to new compounds of formula (I), wherein R1 to R12, P, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: May 22, 2006
    Publication date: April 16, 2009
    Applicant: AstraZeneca AB
    Inventors: Gunnar Nordvall, Carl Petersson, Laszlo Rakos, Daniel Sohn
  • COMPOSITION 064
    Publication number: 20090099203
    Abstract: A pharmaceutical composition which comprises N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide with mannitol and/or microcrystalline cellulose is described.
    Type: Application
    Filed: October 10, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: John David Blyth, Andrew John Day, Kieran James Lennon
  • Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias
    Publication number: 20090099162
    Abstract: There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: February 11, 2008
    Publication date: April 16, 2009
    Applicant: AstraZeneca AB
    Inventors: Annika Bjore, Ulrik Gran, Gert Strandlund
  • Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
    Patent number: 7517898
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and Z are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: April 14, 2009
    Assignee: AstraZeneca AB
    Inventors: Ziping Liu, Daniel Pagé, Christopher Walpole, Hua Yang
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7517989
    Abstract: The present invention provides a compound of formula (I), wherein: Z is (A) OR (B) and wherein the remaining variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of achemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: April 14, 2009
    Assignee: AstraZeneca AB
    Inventors: Christopher Luckhurst, Matthew Perry, Hitesh Sanganee, Brian Springthorpe
  • Environmental Detector
    Publication number: 20090093785
    Abstract: An environmental sensor device for detecting environmental conditions within a pharmaceutical product package is described. The sensor device is a stand alone device that includes: a housing defining the outer dimensions of the sensor device, a humidity sensor, a temperature sensor, a control circuit, a memory circuit, a power source and a communications interface. The housing has outer dimensions that allow it to fit inside a pharmaceutical product package. A system and method for evaluating best before date for pharmaceutical products are also described.
    Type: Application
    Filed: June 28, 2006
    Publication date: April 9, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Helen Brown, Darren Hodson, Rachel Jury, Simon Newey, Aziz-ur Rehman
  • Compositions
    Publication number: 20090093460
    Abstract: Pharmaceutical compositions, oral pharmaceutical compositions, and solid dosage forms comprising up to about 750 mg of 11-piperazin-1-yldibenzo[b,f] [1,4]thiazepine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent are provided.
    Type: Application
    Filed: June 13, 2008
    Publication date: April 9, 2009
    Applicant: AstraZeneca AB
    Inventors: Patricia C. Davis, Jeffrey M. Goldstein, Scott W. Grimm, Raymond F. Suckow, Helen R. Winter
  • Methods of Treating Anxiety and Mood Disorders
    Publication number: 20090093461
    Abstract: Methods of treating at least one symptom or condition associated with Anxiety Disorders and/or Mood Disorders comprising administering an effective amount of a compound of Formula I or its pharmaceutically acceptable salt are provided herein.
    Type: Application
    Filed: June 13, 2008
    Publication date: April 9, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Patricia C. Davis, Jeffrey Goldstein, Scott W. Grimm, Raymond F. Suckow, Helen R. Winter
  • Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases
    Publication number: 20090093485
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).
    Type: Application
    Filed: October 26, 2005
    Publication date: April 9, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Hakan Bladh, Krister Henriksson, Vijaykumar Hulikal, Matti Lepisto
  • Oxazolidinone nicotinic acetylcholine receptor agonists
    Patent number: 7514567
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Q, Ar1, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments for therapy, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: April 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Eifion Phillips
  • Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor ? (PPAR)
    Patent number: 7514471
    Abstract: The present invention provides the S enantiomer of a compound of formula (I) wherein n is 1 or 2 as well as pharmaceutically acceptable salts, solvates, crystalline forms and prodrugs thereof, to processes for preparing such compounds, to their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: April 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Eva-Lotte Alstermark Lindstedt, Anna Christina Olsson, Lanna Li
  • Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (GnRH) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
    Patent number: 7514570
    Abstract: The invention relates to a group of novel pyrazole compounds of Formula (I): wherein: R1, R2, R3, M and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: April 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Thomas Geoffrey Colerick Bird, Mickael Louis Pierre Maudet, Matthias Ferdinand Herdemann
  • Crystalline form of omeprazole
    Patent number: 7514560
    Abstract: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H -benzimidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: April 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Karin Lövqvist, Gunnel Sundén, David Noreland, Ingvar Ymén
  • Process for preparing the calcium salt of rosuvastatin
    Patent number: 7511140
    Abstract: An improved process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl)(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis, is described.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: March 31, 2009
    Assignee: AstraZeneca AB
    Inventors: John Horbury, Nigel Philip Taylor
  • GABAreceptor polypeptides and screening methods
    Patent number: 7507543
    Abstract: The present invention relates to a nucleic acid molecule encoding a human or canine GABAB receptor, or a conservative variant thereof.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: March 24, 2009
    Assignee: AstraZeneca AB
    Inventor: Jonas Ekstrand
  • Spiroazabicyclic heterocyclic compounds
    Patent number: 7507744
    Abstract: A pharmaceutical composition comprising a compound of formula wherein n, m, p, X, Y, W, A, G and D are as defined in the specification, enantiomers thereof, or pharmaceutically acceptable salts thereof, its use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: March 24, 2009
    Assignee: AstraZeneca AB
    Inventors: Eifion Phillips, Robert Mack, John Macor, Simon Semus
  • Cyclopropyl Amide Derivatives 978
    Publication number: 20090076020
    Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.
    Type: Application
    Filed: August 21, 2008
    Publication date: March 19, 2009
    Applicant: ASTRAZENECA AB
    Inventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
  • Compounds
    Publication number: 20090076064
    Abstract: Disclosed are compounds of Formula (I) wherein G, R2, A, D and E are as described in the specification, or pharmaceutically-acceptable salts, or in vivo-hydrolysable precursors thereof. Also disclosed herein is at least one method of making, at least one pharmaceutical composition containing, and at least one method for using at least one compound in accordance with Formula I.
    Type: Application
    Filed: January 3, 2007
    Publication date: March 19, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Rebecca Urbanek, Dean Brown, Gary Steelman, William Blackwell, Steven Wesolowski, Xia Wang